A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a research study to test the combination of two drugs, pembrolizumab and epacadostat
with the goal of benefiting subjects with head and neck cancers where prior or ongoing
regimens with a PD-1 or PD-L1 inhibitor for the treatment of advanced head and neck cancer
after platinum failure.